documentation of the Scientific Advice from the CHMP

Interne Prüfung durch Europäische Arzneimittel-Agentur wird erwartet.

Dear European Medicines Agency,

Under the right of access to documents in the EU treaties, as developed in Regulation 1049/2001, I am requesting documents which contain the following information:
Scientific Advice from the CHMP on 19 March 2008 (EMEA/H/SA/996/2008/PA/II)

In the EMA public assessment report on Defitelio (Defibrotide) manufactured by Gentium (I was very impressed by the scientific accuracy and stringency of the report!), I found the statement that the “applicant received Scientific Advice from the CHMP on 19 March 2008 (EMEA/H/SA/996/2008/PA/II). The Scientific Advice pertained to clinical aspects of the dossier.”
In order to improve our local Guidelines for Trials which are industry co-sonsored, the above mentioned document is of great importance for our Research Institute.

Yours faithfully,

Susanne Matthes

AskEMA, Europäische Arzneimittel-Agentur

Dear Sir/Madam

Re: ASK-6403 access to information request - documentation of the
Scientific Advice from the CHMP received on 18 November 2014

Thank you for submitting your request.

This is an automated response to confirm that we have received your
request; please do not respond to this message.

We endeavour to provide a response to all information enquiries (RFI)
within 2 months according to [1]The European Medicines Agency Code of Good
Administrative Behaviour.

Concerning requests for access to documents (ATD), your enquiry will be
processed according to [2]Regulation (EC) No 1049/2001. You can also refer
to [3]the Agency’s web site for additional information.

This automated response is not an acknowledgement of receipt or
registration for the purpose of the ATD process. Such
acknowledgment/registration will be issued separately following
validation.

Should you need to contact us, please always use in the title of your
email, the reference number ASK-6403, which has been allocated to your
request.

Kind regards

European Medicines Agency
30 Churchill Place | Canary Wharf | London E14 5EU | United Kingdom

Got a question? Ask EMA at [4]www.ema.europa.eu/contact

This message and any attachment contain information which may be
confidential or otherwise protected from disclosure. It is intended for
the addressee(s) only and should not be relied upon as legal advice unless
it is otherwise stated. If you are not the intended recipient(s) (or
authorised by an addressee who received this message), access to this
e-mail, or any disclosure or copying of its contents, or any action taken
(or not taken) in reliance on it is unauthorised and may be unlawful. If
you have received this e-mail in error, please inform the sender
immediately.

Zitate anzeigen

References

Visible links
1. http://www.ema.europa.eu/docs/en_GB/docu...
2. http://www.europarl.europa.eu/RegData/PD...
3. http://www.ema.europa.eu/ema/index.jsp?c...
4. http://www.ema.europa.eu/contact

Dear European Medicines Agency,
Under the right of access to documents in the EU treaties, as developed in Regulation 1049/2001, I requested in November 2014 documents which contain the following information:
Scientific Advice from the CHMP on 19 March 2008 (EMEA/H/SA/996/2008/PA/II). Unfortunately, I did not receive a copy of the document yet. may I kindly remind you to provide me with the respective Information.

Yours faithfully,

Susanne Matthes

EMA Info, Europäische Arzneimittel-Agentur

Dear Sir/Madam,

Thank you for contacting the European Medicines Agency.

If your email is in relation to a request for information (RFI) or a request for access to documents (ATD) from the Agency, it has been forwarded to the relevant team.

Please note that from 1 January 2015 this mailbox will not be used for RFI and ATD requests. If you wish to submit such requests, please use the webform by following the link below:

http://www.ema.europa.eu/ema/index.jsp?c...

For more information on ATD please refer to our guide on access to unpublished documents:

http://www.ema.europa.eu/ema/index.jsp?c...

Best regards,

The European Medicines Agency

Zitate anzeigen